Daniel A Pollyea

37PUBLICATIONS
202CO-AUTHORS
Gene and molecular therapySolid tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (37)

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|May 20, 2026
RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcoma.

|Feb 13, 2026
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia.

Michael K Jones, Jesse Sanchez, Megan Connor

|Aug 26, 2025
Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia.

Cristiana O'Brien, Nirvana Nursimulu, Anit Tyagi

|May 21, 2025
Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study.

Curtis A Lachowiez, Mael Heiblig, Gaspar Aspas Requena

|Nov 01, 2024
Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.

Curtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman

Pageof 7

Frequent Collaborators

9 joint publications

Courtney D DiNardo

6 joint publications

Maria L Amaya

5 joint publications

Brian A Jonas

5 joint publications

Craig T Jordan